ArticleMolecular cell2022
Structure of the type V-C CRISPR-Cas effector enzyme.
Article in Molecular cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- BaCas12a3 represents a new subtype of type V CRISPR effector with collateral activity toward tRNA.Nucleic acids research · 2026Article
- Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency.Nature structural & molecular biology · 2026Article
- Phage-associated Cas12p nucleases require binding to bacterial thioredoxin for activation and cleavage of target DNA.Nature microbiology · 2026Article
- Structural basis for target DNA cleavage and guide RNA processing by CRISPR-Casλ2.Communications biology · 2025Article
- Structure of Fanzor2 reveals insights into the evolution of the TnpB superfamily.Nature structural & molecular biology · 2025Article
- DNA target binding-induced pre-crRNA processing in type II and V CRISPR-Cas systems.Nucleic acids research · 2025Article
- AAV-mediated gene therapies by miniature gene editing tools.Science China. Life sciences · 2024Review
- Biology and applications of CRISPR-Cas12 and transposon-associated homologs.Nature biotechnology · 2024Review
- Article
- CRISPR technology in human diseases.MedComm · 2024Review
- TracrRNA reprogramming enables direct PAM-independent detection of RNA with diverse DNA-targeting Cas12 nucleases.Nature communications · 2024Article
- AlPaCas: allele-specific CRISPR gene editing through a protospacer-adjacent-motif (PAM) approach.Nucleic acids research · 2024Article
- Molecular basis and engineering of miniature Cas12f with C-rich PAM specificity.Nature chemical biology · 2024Article
- CRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications.Iranian biomedical journal · 2023Review
- Structural transitions upon guide RNA binding and their importance in Cas12g-mediated RNA cleavage.PLoS genetics · 2023Article
- Mechanistic and evolutionary insights into a type V-M CRISPR-Cas effector enzyme.Nature structural & molecular biology · 2023Article
- The Transposon-Encoded Protein TnpB Processes Its Own mRNA into ωRNA for Guided Nuclease Activity.The CRISPR journal · 2023Article
- Advances in CRISPR/Cas gene therapy for inborn errors of immunity.Frontiers in immunology · 2023Review
- Development of CRISPR Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson's disease.Frontiers in neuroscience · 2023Review
- Structural insights into target DNA recognition and cleavage by the CRISPR-Cas12c1 system.Nucleic acids research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
RNA-guided CRISPR-Cas nucleases are widely used as versatile genome-engineering tools. Recent studies identified functionally divergent type V Cas12 family enzymes. Among them, Cas12c2 binds a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA) and recognizes double-stranded DNA targets with a short TN PAM. Here, we report the cryo-electron microscopy structures of the Cas12c2-guide RNA binary complex and the Cas12c2-guide RNA-target DNA ternary complex. The structures revealed that the crRNA and tracrRNA form an unexpected X-junction architecture, and that Cas12c2 recognizes a single T nucleotide in the PAM through specific hydrogen-bonding interactions with two arginine residues. Furthermore, our biochemical analyses indicated that Cas12c2 processes its precursor crRNA to a mature crRNA using the RuvC catalytic site through a unique mechanism. Collectively, our findings improve the mechanistic understanding of diverse type V CRISPR-Cas effectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.